• Core Competences
• Pipeline
• Business Development
• Investor
• Join Us
• About Us
• Cancer
• Biodefence
• Infectious Diseases

Cancer

• Prostate Cancer
  • Current Treatment Options
  • PROSTVAC®
• Breast Cancer

PROSTVAC® specifications

• PROSTVAC® is administered subcutaneously and induces a specific, targeted immune response that attacks the cancerous cells in the prostate
• PROSTVAC® is a sequentially dosed combination of two different Poxviruses which each encode prostate specific antigen (PSA) plus three immune enhancing co-stimulatory molecules, B7.1, ICAM-1, and Lfa-3 (TRICOM). The first Poxvirus is Vaccinia-PSA-TRICOM, which is replication competent and is good for immune priming. The second Poxvirus is Fowlpox-PSA-TRICOM, a non-replicating virus, which is good for repetitive immune boosting.
• PROSTVAC® is given as monthly injections starting with a Vaccinia-PSA-TRICOM priming dose and followed by 6 monthly Fowlpox-PSA-TRICOM boosts.
• PROSTVAC® is a drug-like biological therapy, which has gone through several generations of improvements, and multiple clinical trials

• PROSTVAC® is being developed in collaboration with the National Cancer Institute (NCI) of the United States, under a formal collaborative research and development agreement (CRADA)